## Depression Care Path

### Screening and Diagnosis

**Diagnosis:** Major Depressive Disorder is defined as depressed mood, markedly diminished interest or pleasure in almost all activities, >5% body weight changes in 1 month, insomnia/hypersomnia, fatigue, loss of energy, feelings of worthlessness, hopelessness, inability to concentrate and/or recurrent thoughts of death. These symptoms should be present most of the day, nearly every-day and cause significant distress or impairment in functioning.

In severe cases of mania or depression, patient may have psychotic symptoms.

**Screening:** Use of an age appropriate depression screening tool is advised. The PHQ-2 is recommended for initial screening. A positive PHQ-2 would trigger further screening using the PHQ-9. The PHQ-9 is widely accepted evidence based self-administered screening tool for depression. Treatment recommended with scores >10.

**IMPORTANT:** If answer to question # 9 is “YES”: assess suicide risk and take emergency action.

**Most common differential diagnoses to consider:**

- Rule out history of a “manic episode” in the patient or family history of Bipolar Disorder as giving anti-depressant medications to treat depressive episode of a Bipolar Disorder may precipitate a manic episode.
- Hypothyroidism
- Anemia
- Substance abuse or over-prescription of CNS depressant medications

---

Please note: The Via Christi Health Alliance in Accountable Care, Inc. (the “ACO”) in consultation with its affiliated ACO providers developed these care pathways and guidelines based on the most recent evidenced based medicine data. The ACO is continually researching and updating its care pathways and guidelines to reflect the most recent evidence based standards. This information is intended to provide health professionals with information to improve the quality of care and ultimately lower the cost of such care to the patients they serve. By providing this evidence based information, it is not the intention of the ACO to provide specific medical advice for particular patients. Rather we urge each provider to review this material when consulting and evaluating the treatment options suitable for their patients. The ACO affiliated providers are solely responsible for confirming the accuracy, timeliness, completeness, appropriateness and helpfulness of this material and making all medical, diagnostic or prescription decisions.
**Treatment**

A. Psychotherapy

B. Pharmacotherapy:

1. Goal of treatment is remission.
2. First line treatment is an SSRI medication such as fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram. Maximum therapeutic benefit seen in 6 weeks. Maximize dose. Watch for gastrointestinal side effects, sexual side effects and restlessness. Gastrointestinal side effects and restlessness are usually transient. Consider potential drug-drug interactions that may occur with fluoxetine, paroxetine and fluvoxamine when used with other medications. Paroxetine is pregnancy category D, all other SSRIs are category C. Watch for QTc prolongation with citalopram. Max dose is 20mg if concomitant use of omeprazole. Max dose of citalopram in patients > 60 years in 20 mg.
3. If patient achieves REMISSION, continue treatment and monitor. If less than 2 episodes of major depression, may try taper and discontinue of medication after 12 months of sustained remission.
4. If PARTIAL RESPONSE, may refer patient for psychotherapy or augment SSRI with one of the following medications:
   - **Aripiprazole**: usually not the first choice for augmentation and would not be recommended at primary care setting. Very expensive. Watch for akathisia. Avoid in patients with obesity, Diabetes Mellitus, Dyslipidemia, age >65 (risk of stroke).
   - **Buspirone**: consider if co-morbid anxiety. Clinically only modest response observed.
   - **Buproprion**: contraindicated in patients with seizure disorder, binging & purging behavior and hx of TBI. Avoid if co-morbid anxiety or chronic heavy alcohol use. Advantage if smoking cessation is desired. Also a good augmentation strategy if sexual side effects were problematic with SSRIs.
   - **Liothyronine**: usually not the first choice for augmentation and would not be recommended at primary care setting. No effect on Thyroid Function Tests.
   - **Lithium**: usually not the first choice for augmentation and would not be recommended at primary care setting. check Renal Function Tests and Thyroid Function Tests. Avoid in females of child bearing age (risk of cardiac defects) and in patients with electrolyte abnormalities. Avoid when patients are taking NSAIDs, ACE inhibitors and thiazide diuretics. Narrow therapeutic index and requires therapeutic drug monitoring with Lithium level. Avoid if high risk of suicide.
   - **Mirtazapine**: consider if poor appetite & insomnia. A good choice if co-morbid gastrointestinal symptoms. Watch for agranulocytosis.
   - **Quetiapine**: usually not the first choice for augmentation and would not be recommended at primary care setting. Avoid in patients with obesity, Diabetes.
Mellitus, Dyslipidemia, age >65 (risk of stroke). Causes sedation, may be used if also targeting insomnia. Also watch for orthostasis which is usually transient.

5. If NO RESPONSE to one trial of SSRI, switch to another SSRI and follow step 3 & 4. Do not use two pharmaceutical agents from same class.

6. If NO RESPONSE to two trials of SSRIs at maximum doses and maximum duration, switch to an SNRI such as duloxetine, venlafaxine, desvenlafaxine or levomilnacipran. Maximum therapeutic benefit seen in 6 weeks. Maximize dose. Watch for orthostasis, gastrointestinal side effects, sexual side effects and restlessness. Orthostasis, gastrointestinal side effects and restlessness are usually transient.

Other Treatment Considerations:

- Remove access to means of self-harm in severe phase of a depressive episode such as firearms. Avoid giving 90 day supply of medications.
- If patient needs emergent mental health services because of suicidal thoughts or self-care failure, send patient to nearest ED. If concerned about safety of the patient and patient is not reachable, can ask law enforcement to do a “welfare check” on the patient.

Please note: The Via Christi Health Alliance in Accountable Care, Inc. (the “ACO”) in consultation with its affiliated ACO providers developed these care pathways and guidelines based on the most recent evidenced based medicine data. The ACO is continually researching and updating its care pathways and guidelines to reflect the most recent evidence based standards. This information is intended to provide health professionals with information to improve the quality of care and ultimately lower the cost of such care to the patients they serve. By providing this evidence based information, it is not the intention of the ACO to provide specific medical advice for particular patients. Rather we urge each provider to review this material when consulting and evaluating the treatment options suitable for their patients. The ACO affiliated providers are solely responsible for confirming the accuracy, timeliness, completeness, appropriateness and helpfulness of this material and making all medical, diagnostic or prescription decisions.
Please note: The Via Christi Health Alliance in Accountable Care, Inc. (the “ACO”) in consultation with its affiliated ACO providers developed these care pathways and guidelines based on the most recent evidenced based medicine data. The ACO is continually researching and updating its care pathways and guidelines to reflect the most recent evidence based standards. This information is intended to provide health professionals with information to improve the quality of care and ultimately lower the cost of such care to the patients they serve. By providing this evidence based information, it is not the intention of the ACO to provide specific medical advice for particular patients. Rather we urge each provider to review this material when consulting and evaluating the treatment options suitable for their patients. The ACO affiliated providers are solely responsible for confirming the accuracy, timeliness, completeness, appropriateness and helpfulness of this material and making all medical, diagnostic or prescription decisions.

<table>
<thead>
<tr>
<th>Reassessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use PHQ-9 to monitor treatment response (12 months out, +/- 30 days).</td>
</tr>
<tr>
<td>Therapeutic drug monitoring where applicable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychoeducation</td>
</tr>
<tr>
<td>Encourage compliance</td>
</tr>
<tr>
<td>Sleep hygiene education</td>
</tr>
<tr>
<td>Community engagement</td>
</tr>
<tr>
<td>Exercise</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialist Consult</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>When to Refer:</strong></td>
</tr>
<tr>
<td>➢ Poor treatment response, intolerable side effects.</td>
</tr>
<tr>
<td>➢ Co-morbid personality disorders, substance abuse or psychotic symptoms.</td>
</tr>
<tr>
<td>➢ Complex psychosocial environment.</td>
</tr>
</tbody>
</table>

References:

1. The Diagnostic and Statistical Manual of Mental Disorders 5th ed.; DSM–5; American Psychiatric Association [APA], 2013